A Phase 1 interventional study of RO7497372 in Diabetic Macular Edema, sponsored by Genentech, Inc.. Active, not recruiting at 38 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 20th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 1, and was the 26th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 14 · Phase 4 2
First in 2007; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 377 across the 25 interventional studies, 736 across the 3 observational. Of the 23 that completed or were terminated, 17 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
3 of the studies in Macular Edema by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04108156Phase 3Hoffmann-La RocheA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | 2027-07-20 |
| NCT05224102Genentech, Inc.A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | 2027-01-26 |
| NCT06680817Hoffmann-La RocheA Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharmacodynamics (PD) in aqueous humor (AH) and blood. Part 2 will evaluate the safety, tolerability, PK, and PD of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive multiple ascending doses of RO7497372, 3 times every 4 weeks (Q4W) as an IVT injection up to Week 8 in the study eye.
Drug: RO7497372
Participants will receive 6 doses of RO7497372, low dose, Q4W followed by 3 doses, every eight weeks (Q8W) as an IVT injection up to Week 44 in the study eye.
Drug: RO7497372
Participants will receive 6 doses of RO7497372, high dose, Q4W followed by 3 doses, Q8W as an IVT injection up to Week 44 in the study eye. Treatment in this arm has been discontinued due to the Sponsor's decision.
Drug: RO7497372
RO7497372 will be administered as IVT injection as per the schedule specified in the arms.
Part 1: Number of Participants With Adverse Events (AEs)
Time frame: Up to 28 Weeks
Part 2: Number of Participants With Intraocular Inflammation (IOI) AEs as Reported by the Investigator
Time frame: Baseline to Week 48
Part 2: Number of Participants With Severe or Serious Drug-Related IOI AEs
Number of participants with severe or serious drug-related IOI AEs severity will be determined according to the DAIDS toxicity grading scale as reported by the Investigator.
Time frame: Baseline to Week 48
Part 2: Number of Participants With Occlusive Retinal Vasculitis AEs as Reported by the Investigator
Time frame: Baseline to Week 48
Part 1: Concentration of RO7497372 in Blood
Time frame: Up to Week 28
Part 1: Concentration of RO7497372 in Aqueous Humor (AH)
Time frame: Up to Week 28
Part 2: Number of Participants With AEs
Number of participants with AEs severity determined according to the DAIDS toxicity grading scale.
Time frame: Up to 56 weeks
Part 2: Number of Participants With Persistent Treatment-induced Anti-drug Antibody (ADAs)
Time frame: Up to 56 weeks
Part 2: Concentration of RO7497372 in AH
Time frame: Up to Week 56
Part 2: Concentration of RO7497372 in Plasma
Time frame: Up to Week 56
Part 2: Change From Baseline in Best Corrected Visual Acuity (BCVA) Score Over Time
BCVA will be measured via Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters using a set of three Precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity (VA) examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicates improvement in VA.
Time frame: From Baseline (Day 1) up to Week 56
Part 2: Absolute Value of BCVA Score Over Time
BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicates improvement in VA.
Time frame: Up to Week 56
Part 2: Percentage of Participants Gaining ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time
BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicates improvement in VA.
Time frame: Up to Week 56
Part 2: Percentage of Participants Avoiding a Loss of ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time
BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicates improvement in VA.
Time frame: Up to Week 56
Part 2: Change From Baseline in Central Subfield Thickness (CST) Over Time
CST is defined as the average thickness of the central 1-mm circle of the ETDRS grid centered to the fovea measured between the internal limiting membrane and the Bruch's membrane. CST will be determined by CRC evaluation of SD-OCT images.
Time frame: From Baseline (Day 1) up to Week 56
Part 2: Absolute Value of CST Over Time
CST is defined as the average thickness of the central 1-mm circle of the ETDRS grid centered to the fovea measured between the internal limiting membrane and the Bruch's membrane. CST will be determined by CRC evaluation of SD-OCT images.
Time frame: Up to Week 56
Part 2: Percentage of Participants With Absence of DME Over Time
Absence of DME is defined as CST \< 325 micrometre (μm) by spectral domain optical coherence tomography (SD-OCT).
Time frame: Up to Week 56
Part 2: Percentage of Participants With Absence of Intraretinal Fluid and/or Subretinal Fluid Over Time
Presence of intraretinal and subretinal fluid will be determined by CRC evaluation of SD -OCT images.
Time frame: Up to Week 56
Part 2: Percentage of Participants With ≥ 2-step Diabetic Retinopathy Severity Scale (DRSS) Improvement From Baseline on the ETDRS DRSS Over Time
The DRSS will be graded according to ETDRS grading schedules from report 18 JOVS, February 1998, Vol. 39, No. 2. ETDRS DRSS is 13 step scale which measures severity of diabetic retinopathy (DR). The DRSS scores vary from 10 (DR absent) to 90 (ungradable proliferative diabetic retinopathy(PDR)). Higher levels indicate higher severity.
Time frame: Up to Week 56
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Nov 2026, 47 months after the start.
Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 47 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.